Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 858M 741M 697M 634M 1.19B 82.08B 1.21B 8.16B 3.19B 41.1B 3.22B 3.15B 137B P/E 2026 *
9.3x
P/E 2027 * 7.64x
Enterprise Value 1.16B 1B 943M 858M 1.61B 111B 1.64B 11.05B 4.32B 55.63B 4.36B 4.27B 185B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.33x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day+4.29%
1 week+1.11%
Current month+5.37%
1 month+11.73%
3 months+21.45%
6 months-26.15%
Current year-21.55%
1 week 19.55
Extreme 19.55
21.07
1 month 18.5
Extreme 18.5
22.64
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 28/02/1996
Chief Operating Officer 76 28/02/1996
Director of Finance/CFO 58 31/03/2014
Director TitleAgeSince
Chairman 76 28/02/1996
Director/Board Member 79 28/02/1996
Director/Board Member 58 03/08/2022
Date Insider Type Main position Quantity % Market Cap.
11/08/26 Sell

Director

-7,973 0.0181%
07/08/26 Fiscal year

Chief Financial Officer

18,286 0.0415%
09/07/26 Free

Director

24,532 0.0556%
Change 5-day change 1-year change 3-year change Capi.($)
+4.29%+1.11%-30.45%-61.14% 858M
-2.18%-0.27%+72.77%+119.79% 1,078B
-0.35%+0.71%+49.42%+50.53% 632B
-0.24%+1.54%+22.05%+64.06% 443B
-1.99%-3.32%+41.98%+34.08% 356B
-1.05%-2.81%+24.22%+34.67% 289B
-2.12%-3.67%-1.09%+3.11% 245B
-0.75%+0.82%+42.72%+58.76% 226B
-1.19%-3.41%-9.18%-52.41% 204B
+0.18%+3.81%+16.18%+73.17% 171B
Average -0.54%+1.48%+22.86%+32.46% 364.46B
Weighted average by Cap. -1.27%+1.30%+41.60%+62.40%

Financials

2026 *2027 *
Net sales 748M 646M 607M 552M 1.04B 71.5B 1.05B 7.11B 2.78B 35.81B 2.81B 2.75B 119B 784M 677M 637M 579M 1.09B 75.01B 1.11B 7.46B 2.92B 37.56B 2.95B 2.88B 125B
Net income 99.32M 85.78M 80.61M 73.31M 138M 9.5B 140M 944M 369M 4.76B 373M 365M 15.8B 115M 99.69M 93.68M 85.19M 160M 11.04B 163M 1.1B 429M 5.53B 433M 424M 18.37B
Net Debt 303M 262M 246M 224M 421M 29.01B 428M 2.89B 1.13B 14.53B 1.14B 1.11B 48.28B 184M 159M 149M 136M 256M 17.61B 260M 1.75B 685M 8.82B 691M 676M 29.3B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
14/08/26 US$21.01 +4.11% 156,033
13/08/26 US$20.18 +1.00% 526,116
12/08/26 US$19.98 -2.15% 343,843
11/08/26 US$20.42 +0.54% 570,493
10/08/26 US$20.31 -2.26% 645,749
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.18USD
Average target price
22.00USD
Spread / Average Target
+9.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock